{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T08:11:42Z","timestamp":1787731902854,"version":"build-2784847793"},"reference-count":21,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T00:00:00Z","timestamp":1633478400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.jiac.2021.10.002","type":"journal-article","created":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T04:00:46Z","timestamp":1634011246000},"page":"103-107","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Concurrence of imatinib-induced massive pleural\/pericardial effusion and Campylobacter bacteremia in an adolescent with chronic myeloid leukemia"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5380-450X","authenticated-orcid":false,"given":"Po-Yu","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boon Fatt","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Min","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Nien","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An-Kuo","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Jung","family":"Kung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6460-3677","authenticated-orcid":false,"given":"Ling-Chun","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Ju","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2021.10.002_bib1","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiac.2021.10.002_bib2","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiac.2021.10.002_bib4","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1038\/s41375-020-0805-1","article-title":"Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study","volume":"34","author":"Cortes","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.jiac.2021.10.002_bib5","author":"Yang"},{"key":"10.1016\/j.jiac.2021.10.002_bib6","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jiac.2021.10.002_bib12","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1086\/319760","article-title":"Campylobacter jejuni infections: update on emerging issues and trends","volume":"32","author":"Allos","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2021.10.002_bib13","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1469-0691.2004.01028.x","article-title":"Campylobacter infections of the pericardium and myocardium","volume":"11","author":"Uzoigwe","year":"2005","journal-title":"Clin Microbiol Infect"},{"issue":"Suppl 2","key":"10.1016\/j.jiac.2021.10.002_bib7","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/j.cmi.2018.02.009","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors)","volume":"24","author":"Reinwald","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jiac.2021.10.002_bib8","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.4049\/jimmunol.1601695","article-title":"Imatinib and nilotinib off-target effects on human NK cells, monocytes, and M2 macrophages","volume":"199","author":"Bellora","year":"2017","journal-title":"J Immunol"},{"key":"10.1016\/j.jiac.2021.10.002_bib9","first-page":"336","article-title":"[A study of 30 patients with bacteremia due to Campylobacter spp]","volume":"108","author":"Font","year":"1997","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.jiac.2021.10.002_bib10","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1556\/EuJMI.2.2012.1.11","article-title":"Campylobacter bacteremia: a rare and under-reported event?","volume":"2","author":"Louwen","year":"2012","journal-title":"Eur J Microbiol Immunol (Bp)"},{"key":"10.1016\/j.jiac.2021.10.002_bib11","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s004300050056","article-title":"Differential uptake and killing potential of Campylobacter jejuni by human peripheral monocytes\/macrophages","volume":"186","author":"Wassenaar","year":"1997","journal-title":"Med Microbiol Immunol"},{"key":"10.1016\/j.jiac.2021.10.002_bib14","first-page":"1","article-title":"A 50-year-old man with pleural effusion and chronic myelogenous leukemia","volume":"6","author":"Gerogianni","year":"2005","journal-title":"Internet J Pulm Med"},{"key":"10.1016\/j.jiac.2021.10.002_bib15","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1600-0609.2004.00347.x","article-title":"Pleural-pericardic effusion as uncommon complication in CML patients treated with Imatinib","volume":"74","author":"Breccia","year":"2005","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jiac.2021.10.002_bib16","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jclinane.2017.12.005","article-title":"Pleural and pericardial effusions in patient on tyrosine kinase inhibitor","volume":"45","author":"Pysyk","year":"2018","journal-title":"J Clin Anesth"},{"key":"10.1016\/j.jiac.2021.10.002_bib17","first-page":"14004","article-title":"Imatinib induced delayed and refractory generalized fluid retention: a case report and review of literature","volume":"19","author":"Abdelmaksoud","year":"2019","journal-title":"Biomed J Sci Tech Res"},{"key":"10.1016\/j.jiac.2021.10.002_bib18","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2019-229975","article-title":"Imatinib-induced pericardial effusion in a child","volume":"12","author":"Terry","year":"2019","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.jiac.2021.10.002_bib19","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1038\/leu.2009.111","article-title":"Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia","volume":"23","author":"Giles","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.jiac.2021.10.002_bib21","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1016\/j.clinthera.2019.10.009","article-title":"Utility of therapeutic drug monitoring of imatinib, nilotinib, and dasatinib in chronic myeloid leukemia: a systematic review and meta-analysis","volume":"41","author":"Garc\u00eda-Ferrer","year":"2019","journal-title":"Clin Therapeut"},{"key":"10.1016\/j.jiac.2021.10.002_bib22","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s11095-018-2551-x","article-title":"Pharmacokinetic and pharmacodynamic considerations for drugs binding to alpha-1-acid glycoprotein","volume":"36","author":"Smith","year":"2018","journal-title":"Pharm Res"},{"key":"10.1016\/j.jiac.2021.10.002_bib23","doi-asserted-by":"crossref","first-page":"569843","DOI":"10.3389\/fphar.2020.569843","article-title":"Factors influencing the steady-state plasma concentration of imatinib mesylate in patients with gastrointestinal stromal tumors and chronic myeloid leukemia","volume":"11","author":"Chen","year":"2020","journal-title":"Front Pharmacol"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X21002701?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X21002701?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:03:46Z","timestamp":1761159826000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X21002701"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S1341321X21002701"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2021.10.002","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Concurrence of imatinib-induced massive pleural\/pericardial effusion and Campylobacter bacteremia in an adolescent with chronic myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2021.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}